** Shares of China's JD Health International climb 3.6% to HK$28.85, on track for biggest one-day pct gain since Dec 28
** Stock biggest pct gainer in Hang Seng Index and Hang Seng China Enterprises Index ; second biggest in Hang Seng Tech Index
** HSBC maintains "buy" rating on JD Health and lifts TP to HK$48 from HK$47.50 on better-than-expected top-line outlook for 4Q23 and 1Q24 as recent wave of respiratory illness in China bolstered demand; also cites firm's plans to expand offline pharmacy footprint
** Nomura keeps "buy" on stock, saying 2H23 results likely above estimates on increased 4Q revenue due to higher demand for pharmaceuticals amid spike in influenza cases
** Hong Kong stock of JD.com slips 0.9%
** Hang Seng Tech Index and Hang Seng China Enterprises Index both slip 0.1% while Hang Seng Index
adds 0.2%
** Stock down ~27% YTD
(Reporting by Donny Kwok)
((donny.kwok@thomsonreuters.com))
Comments